Serology
In ILIT after SCIT- 10 000, the allergen specific IgG4levels decreased by 41% in the placebo group during the course of the study. In the active group the IgG4 levels were doubled 4 weeks after treatment with an increase from median level 3.4 to 8.3 mg/L but had returned to baseline levels 8 months after treatment. We could not find any correlation between the IgG4induction and CSMS.
In ILIT de novo- 3000 there was also a statistically significant, but modest, increase in allergen specific IgG4 levels. 4 weeks after active treatment the levels had increased by about 42% from median 0.24 to 0.34 mg/L, p=0.0001. 8 months after treatment the levels had declined towards baseline; median specific IgG4 was 0.25 mg/L, p=0.03. The placebo group did not change.
The allergen specific IgE antibodies increased transiently in the active group 4 weeks after treatment in both studies. At the follow up 8 months after treatment the levels had normalized in ILIT after SCIT- 10 000 but were still elevated compared to the baseline level in ILIT de novo- 3000. The placebo group did not change. (See Figure 4 and Table E3.)